



Roche Innovation Center Copenhagen A/S

Fremtidsvej 3, 2970 Hørsholm, Denmark

CVR. NO 20 69 00 03

Annual Report for the period 1 January - 31 December 2021

(24th Year of Accounting)

Approved on the Ordinary Annual General Meeting
30-Jun-22

As Chairman:

DocuSigned by:

Louise Homøe

7E0FFC90A5704DD...

This report contains 24 pages incl. frontpage

Content	Page
Statement by the Executive Board and Board of Directors	2
Independent Auditor's report	3
Management's review	6
Financial highlights	7
Operating review	8
Financial statements 1 January - 31 December	10
Income statement	10
Balance sheet	11
Statement of changes in equity	12
Notes to the financial statements	14

Statement by the Executive Board and Board of Directors

The Executive Board and Board of Directors have considered and approved the annual report of Roche Innovation Center Copenhagen A/S for the year 1 January - 31 December 2021.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2021, and of the results of the Company's operations for the financial year 1 January - 31 December 2021.

Further, in our opinion, the Management's review includes a fair review of developments in the Company's operations and financial matters, result for the year and the Company's financial position.

We recommend that the annual report be approved at the annual general meeting.

Executive Board:

DocuSigned by:
Darine Ghanem
5C7AF7211CE040B...

Darine Ghanem
Managing Director

Board of Directors:

DocuSigned by:
Sylke Pöhling
519A276883F0459...

Sylke Pöhling
(Chairman)

DocuSigned by:
Beat Krähenmann
E9962517519B46F...

Beat Christoph
Krähenmann

DocuSigned by:
Darine Ghanem
5C7AF7211CE040B...

Darine Ghanem

Independent Auditor's report

To the shareholder of Roche Innovation Center Copenhagen A/S

Opinion

We have audited the financial statements of Roche Innovation Center Copenhagen A/S for the financial year 1 January – 31 December 2021 comprising income statement, balance sheet, statement of changes in equity, and notes, including accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's assets, liabilities and financial position at 31 December 2021 and of the results of the Company's operations for the financial year 1 January – 31 December 2021 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's responsibilities for the audit of the financial statements" section of our report.

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion

Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control, that Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Independent Auditor's report

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance as to whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements in Denmark will always detect a material misstatement when it exists. Misstatements may arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of financial statement users made on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgement and maintain professional scepticism throughout the audit. We also

- identify and assess the risks of material misstatement of the company financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control.
- obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Independent Auditor's report

Statement on the Management's review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether the Management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of the Management's review.

Copenhagen, 30 June, 2022

KPMG
Statsautoriseret Revisionspartnerselskab
CVR no 25 57 81 98

Henrik Barner Christiansen
State Authorised
Public Accountant
mne10778

Management's review

Company details

Roche Innovation Center Copenhagen A/S (RICC A/S)

Fremtidsvej 3

DK-2970 Hørsholm

DENMARK

Telephone:

+45 45 17 98 00

Webpage:

http://www.roche.com/research_and_development/who_we_are/how_we_work/our_structure/pred.htm

Registration No.:

20 69 00 03

Established:

1998

Registered office:

Rudersdal

Board of Directors

Sylke Pöhling (Chairman)

Darine Ghanem

Beat Christoph Krähenmann

Executive Board

Darine Ghanem

Auditor

KPMG

Statsautoriseret Revisionspartnerselskab

Dampfærgevej 28

DK-2100 Copenhagen

CVR: 25 57 81 98

Annual general meeting

The annual general meeting is to be held on June 30th 2022

Management's review

Financial highlights

	2021	2020	2019	2018	2017
	TDKK	TDKK	TDKK	TDKK	TDKK
Income Statement					
(1 January - 31 December)					
Gross Profit	133,722	274,294	141,402	202,065	175,825
Operating Profit	9,356	167,637	44,200	67,793	59,106
Results from Financial activities	(78)	(53)	(30)	1,462	(688)
Profit/Loss for the year	4,549	(155,848)	45,880	57,874	38,263
Balance Sheet					
(As per 31 December)					
Total Assets	68,827	112,956	243,368	236,626	241,198
hereof:					
Cash and cash equivalents	-	7	7	7	8
Trade receivables	1,630	1,481	3,154	1,761	3,399
Tangible assets	58,822	52,400	44,021	39,999	37,493
<i>Investment in property, plant and equipment</i>	16,186	15,297	-	12,753	9,526
Financial assets	4,445	4,302	4,213	4,175	3,926
Total Equity and liabilities	68,827	112,956	243,368	236,626	241,198
hereof:					
Equity	(4,883)	(6,006)	209,842	163,962	156,088
Current Liabilities	73,710	113,983	33,526	69,112	78,007
Non-current liabilities	-	4,979	-	3,551	7,103
(As per 31 December)					
Gross margin ratio	77.8%	90.6%	84.1%	83.7%	85.0%
Net margin ratio	2.6%	-51.5%	27.3%	24.0%	18.5%
Equity ratio	-7.1%	-5.3%	86.2%	69.3%	64.7%

Financial Ratios

Financial ratios are calculated in accordance with the Danish Society of Financial Analysts' guidelines on the calculation of financial ratios "Recommendations and Ratios" issued by the Danish Society of Financial Analysts.

The financial ratios stated in the survey of financial highlights have been calculated as follows:

$$\text{Gross margin ratio} = \frac{\text{Gross Profit} \times 100}{\text{Revenue}}$$

$$\text{Net margin ratio} = \frac{\text{Profit/Loss for the year} \times 100}{\text{Revenue}}$$

$$\text{Equity ratio} = \frac{\text{Equity at year end} \times 100}{\text{Total equity and liabilities at year end}}$$

Management's review

Operating review 2021

Roche Innovation Center Copenhagen A/S as part of the Roche Group

Roche Innovation Center Copenhagen A/S (hereinafter RICC A/S) is part of the Roche Group's pharma Early Research & Development organization (pRED) and performs its research activities in Hørsholm under a contract research agreement for the Group.

Principal activities

Roche Innovation Center Copenhagen is a leader in the rapidly emerging field of RNA-targeted drugs, where it is exploiting its proprietary Locked Nucleic Acid (LNA) platform to discover important novel medicines across multiple therapeutic areas. Drugs directed against RNA targets have the potential to transform human medicine, making drug discovery, development and manufacturing more efficient, faster and less error prone than ever before. At the same time, this novel class of drugs offers the means to address disease targets that have previously been undruggable with conventional drug therapies such as small molecules or antibodies.

Roche is continuously investing in its drug discovery and technology platform, bringing together a multidisciplinary team of scientists with experience, talent and commitment to deliver broadly on the promise of RNA medicines.

RICC A/S's result for 2021 is considered satisfactory with a profit before tax of DKK 7.4M versus previous year's loss of DKK 167M. The significant change is due to the settlement agreement in 2020 between Roche and Santaris Sellers for all outstanding contingent considerations, which was a one-time transaction.

Uncertainties relating to recognition or measurement

There are no uncertainties related to recognition or measurement that has affected the presentation of the annual accounts for 2021, except for what is mentioned in note 10.

Outlook

The existing contract research agreement between RICC A/S and F. Hoffmann-La Roche Ltd. enables to maintain a stable financial situation and operating activities of the Company. Therefore, as part of the Roche group, RICC A/S expects a stable activity level and profit for the coming year.

Risks

The company is not exposed to any special risks besides what are normal risks of the business.

Research and development activities

The RICC team is headed by Bo Ritsmar and comprises research groups in chemistry, oligo synthesis, molecular biology and bioinformatics.

Effect on the external environment

Management is aware of the external environment and aims to reduce the environmental impact of the company's operations to a minimum.

There are indirect, general effects resulting from the ongoing conflict between the Ukraine and Russia like high inflation rates and increasing prices for energy affecting RICC A/S.

However, these effects are assessed to be not material.

As RICC A/S does not have any customers, vendors or assets in the respective countries and no shortages in the supply chain are expected there no direct effects on RICC A/S.

The above assessment is reflecting the current state of knowledge and could change in the future if unforeseen developments occur.

Human resources and intellectual capital

It is of vital importance when dealing in research, that the employees of the company possess the required scientific expertise. This knowledge is increased and maintained through further education and by recruiting employees with a high level of education and knowledge.

Open issues

The Danish Tax Agency (Skattestyrelsen) started in August 2018 a tax audit of RICC A/S relating to the fiscal years 2013 - 2017. Based on this tax audit the Danish Tax Agency concluded in September 2020 that the taxable income for the year 2015 is to be increased. This resulted in an adjustment of the tax amount for the year 2015. RICC A/S has filed a complaint against the assessment before the National Tax Tribunal (Landsskatteretten), but is simultaneously pursuing a resolution by way of a mutual agreement procedure. Further, RICC A/S has paid the additional potential tax of DKK 288M late 2020 to avoid interest and penalties to be paid in case the position of the Danish Tax Agency will be confirmed by the competent authorities/National Tax Tribunal.

Subsequent events

Since year-end no events have occurred, which could have a significant impact on the Company's financial position.

Financial statements 1 January - 31 December

Income statement

1 January - 31 December 2021

TDKK	Note	2021	2020
Gross profit		<u>133,722</u>	<u>274,294</u>
Staff costs	2	(57,764)	(57,666)
Research and Development costs		(58,690)	(42,921)
Depreciation		(7,912)	(6,070)
Operating profit		<u>9,356</u>	<u>167,637</u>
Loss from sale of tangible assets		(1,853)	(848)
Financial income	3	95	0
Financial expense	3	(173)	(53)
Operating profit before tax		<u>7,425</u>	<u>166,736</u>
Tax	4	(2,876)	(322,584)
Net Profit/Loss for the year		<u><u>4,549</u></u>	<u><u>(155,848)</u></u>

Financial statements 1 January - 31 December

Balance sheet

31 December 2021

TDKK	Note	2021	2020
ASSETS			
Non-current assets			
Property, plant and equipment	5	<u>58,822</u>	<u>52,400</u>
Total property, plant and equipment		58,822	52,400
Deposits		<u>4,445</u>	<u>4,302</u>
Total investments		4,445	4,302
Total non-current assets		<u>63,267</u>	<u>56,702</u>
Inventories		<u>-</u>	<u>6,723</u>
Total inventories		-	6,723
Trade receivables		1,630	1,481
Intercompany receivables		1,290	46,188
Other receivables		1,903	1,406
Prepayments	6	<u>737</u>	<u>449</u>
Total Receivables		5,560	49,524
Cash at bank and in hand		-	7
Total current assets		<u>5,560</u>	<u>56,254</u>
TOTAL ASSETS		<u><u>68,827</u></u>	<u><u>112,956</u></u>

Financial statements 1 January - 31 December

Balance sheet

31 December 2021

TDKK	Note	2021	2020
EQUITY AND LIABILITIES			
Share capital	7	100,133	100,133
Retained earnings		<u>(105,016)</u>	<u>(106,139)</u>
Total equity		(4,883)	(6,006)
Liabilities			
Non-current liabilities			
Other Payables	8	-	<u>4,979</u>
Total non-current liabilities		-	4,979
Current liabilities			
Trade payables		12,720	6,893
Intercompany payables		3,386	33,748
Intercompany payables (Cash Pool)		37,108	51,623
Other payables including tax payable		15,553	17,019
Deferred tax liability	9	<u>4,943</u>	<u>4,700</u>
Total current liabilities		73,710	113,983
Total liabilities		<u>73,710</u>	<u>118,962</u>
TOTAL EQUITY AND LIABILITIES		<u>68,827</u>	<u>112,956</u>
Contingencies, etc.	10		
Related party disclosures and transactions	11		

Statement of changes in equity

Equity	<i>Share Capital</i>	<i>Retained earnings</i>	<i>Total</i>
TDKK			
Equity 1 January 2021	100,133	(106,139)	(6,006)
Net profit for the year	-	4,549	4,549
Adjustments to prior years	-	(3,426)	(3,426)
Equity 31 December 2021	100,133	(105,016)	(4,883)

Notes to the financial statements

1 Accounting policies

The annual report of Roche Innovation Center Copenhagen A/S for 2021 has been prepared in accordance with the provisions applying to reporting class C medium-sized entities under the Danish Financial Statements Act.

The accounting policies used in the preparation of the financial statements are consistent with those of last year.

With reference to the Danish Financial Statement section 86 (4), the cash flow statement is omitted. Instead we refer to the Annual Report for Roche Holding AG, Basel, Switzerland. This can be found on <https://www.roche.com/investors/annualreport21.htm>

The functional currency is DKK and is unchanged compared to prior years.

Foreign currency translation

On initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date.

Foreign exchange differences arising between the exchange rates at the transaction date and at the date of payment are recognised in the income statement as financial income or expense.

Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and at the date at which the receivable or payable arose or was recognized in the latest consolidated and parent company financial statements is recognized in the income statement as financial income or expense.

Notes to the financial statements

1 Accounting policies (continued)

Income Statement

Revenue

Income from up-front payments, milestone payments, and other income from research and development contracts is recognized in accordance with the terms of the agreements, when it is considered realized or realizable and earned, when the amount of revenue can be measured reliably, and when the economic benefit associated with the transaction will flow to the company.

The company defers recognition of non-refundable upfront fees and recognize them into revenue on a straight-line basis over the estimated period of the company's expected performance. The period over which the revenue is recognized may be adjusted to take into account any delays or acceleration in the development of the applicable product candidate or any extension or shortening of the applicable performance period.

Gross profit

With reference to the Danish Financial Statements Act section 32, management decided to aggregate gross revenue, cost of sales and other external cost and disclose only gross profit.

Cost of sales

Cost of sales comprises costs of sales for the financial year measured at cost, adjusted for ordinary inventory write-downs.

Other external costs

Other external costs comprise expenses of a secondary nature as viewed in relation to the Entity's primary activities such as infrastructure costs, consulting fees, communication and legal costs.

Staff cost

Staff cost includes wages and salaries, social security cost and other employee related cost.

Research and development costs

Research and development costs include research costs and costs of development projects that do not meet the criteria for recognition in the balance sheet.

Depreciation and impairment losses

Depreciation and impairment losses relating to tangible assets and property, plant and equipment comprise depreciation and impairment losses for the financial year, calculated on the basis of the residual values and useful lives of the individual assets. Impairment tests are performed whenever internal or external indicators suggest that the value of an asset may be impaired.

Notes to the financial statements

1 Accounting policies (continued)

Loss from sale of tangible assets

Loss from sale of tangible assets comprises items secondary to the activities of the company, including gain on the disposal of property, plant and equipment.

Financial expenses

Financial expenses comprise interest, realized and unrealized exchange adjustment etc.

Tax

Tax for the year, which consist of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity. The tax effect of 2015 taxable income adjustments claimed by the Danish Tax Authorities has been booked as "Adjustment to previous year tax income" in the Income statement.

The Company is jointly taxed with other Danish associated companies. The current Danish income tax is allocated among the jointly taxed entities proportionally to their taxable income (full allocation with a refund concerning tax losses).

Balance accounts

Property, plant and equipment

Tangible fixed assets are stated at cost less accumulated depreciation. Depreciation is provided under the straight-line method over the following periods:

Equipment	3 - 10 years
Leasehold Improvement	5 - 10 years
IT & Software	3 - 5 years

The useful life and residual value are reassessed annually. Scrap value is estimated to 0. Changes are treated as accounting estimates, and the effect on depreciation is recognised prospectively. Cost comprises the purchase price and any costs directly attributable to the acquisition until the date when the asset is available for use. Property, plant and equipment and Leasehold improvements are written down to the lower of recoverable amount and carrying amount.

Gains and losses on the disposal of property, plant and equipment are stated as the difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses are recognised in the income statement as other operating income or other operating costs, respectively.

Leases

Payments relating to operating Leases and other leases are recognized in the income statement over the term of the Lease. The company's total obligation relating to operating Leases and other leases is disclosed as well as contractual obligations and contingencies, etc.

Notes to the financial statements

1 Accounting policies (continued)

Impairment of fixed assets

The carrying amount of intangible assets and property, plant and equipment is subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation or amortisation.

Impairment tests are conducted of individual assets or groups of assets when there is an indication that they may be impaired. Write-down is made to the recoverable amount if this is lower than the carrying amount.

The recoverable amount is the higher of an asset's net selling price and its value in use. The value in use is determined as the present value of the forecast net cash flows from the use of the asset or the group of assets, including forecast net cash flows from the disposal of the asset or the group of assets after the end of the useful life. Previously recognised write-downs are reversed when the basis for the write-down no longer exists.

Inventories

Inventories are measured at cost in accordance with the FIFO method. Where the net realisable value is lower than cost, inventories are written down to this lower value.

The net realisable value of inventories is calculated as the sales amount less costs of completion and costs necessary to make the sale and is determined taking into account marketability, obsolescence and development in expected selling price.

Receivables

Receivables are measured at amortised cost. Write-down is made for bad debt losses based on an individual assessment of receivables.

Prepayments

Prepayments assets, comprise costs incurred concerning subsequent financial years.

Cash and cash equivalents

Cash and cash equivalents comprise cash and short-term marketable securities with a term of three months or less which are subject to an insignificant risk of changes in value. The entity does not hold any short-term marketable securities.

Notes to the financial statements

1 Accounting policies (continued)

Equity

Corporation tax and deferred tax

The Company is covered by the Danish rules of compulsory joint taxation of the Roche Groups Danish affiliates. Roche A/S (CVR 25230515) is the administration company for the joint taxation and as such, settles all payments of corporate taxes towards tax authorities.

Current tax payable and receivable is recognised in the balance sheet as tax computed on the taxable income for the year, adjusted for tax on the taxable income of prior years and for tax paid on account. Deferred tax is measured using the balance sheet liability method on all temporary differences between the carrying amount and the tax value of assets and liabilities measured on the planned use of the asset or settlement of the liability, respectively. However, deferred tax is not recognised on temporary differences relating to office buildings non-deductible for tax purposes and other items where temporary differences arise at the date of acquisition without affecting either profit/loss or taxable income.

Deferred tax assets, including the tax value of tax loss carryforwards, are recognised at the expected value of their utilisation within the foreseeable future; either as a set-off against tax on future income or as a set-off against deferred tax liabilities in the same legal tax entity. Any deferred net assets are measured at net realisable value.

Deferred tax is measured in accordance with the tax rules and at the tax rates applicable at the balance sheet date when the deferred tax is expected to crystallise as current tax. Changes in deferred tax as a result of changes in tax rates are recognised in the income statement or equity, respectively.

Other financial liabilities

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.

Notes to the financial statements

	2021	2020
	TDKK	TDKK
2 Staff Costs		
Wages and salaries	50,749	50,836
Pensions	6,837	3,716
Other social security costs	178	214
Total staff costs	<u>57,764</u>	<u>57,666</u>
Average number of full-time employees	<u>70</u>	<u>63</u>
Remuneration of the Company's Management and Board of Directors is not disclosed pursuant to section 98b(3)(ii) of the Danish Financial Statements Act.		
Long-term award program		
The program consists of a mix of Stock-Settled Stock Appreciation Rights (S-SARs) and Performance Share Plan (PSP) the employee can decide on a preferred mix based on available combinations. The long-term award program is granted by the Roche Group exclusive to selected employees of RICC A/S. Concerning all activity regarding RICC A/S the long-term award program is solely offered to RICC A/S employees. The total costs related to the long-term award program of DKK 415 thousand (2020: DKK 283 thousand) is included in staff costs and not further detailed as per the Danish Financial Statement Act, sec. 98 (2), 2.		
3 Financial expense		
Intercompany interest expense	(116)	(43)
Other financial expense	(57)	(10)
Total financial expense	<u>(173)</u>	<u>(53)</u>
4 Tax on profit		
Current tax	1,181	33,406
Change in deferred tax	466	2,781
Adjustment to previous year tax income	1,451	286,397
Adjustment to previous year deferred tax income	(222)	-
Tax in the year	<u>2,876</u>	<u>322,584</u>

Notes to the financial statements

5 Property, plant and equipment

TDKK	IT & Software	Leasehold Improvement	Equipment	Total
Cost at 1 January 2021	2,947	17,200	60,904	81,051
Additions	113	5,970	10,103	16,186
Disposal	-	-	(5,762)	(5,762)
Reclassification	(824)	(959)	1,783	-
Cost at 31 December 2021	<u>2,237</u>	<u>22,211</u>	<u>67,028</u>	<u>91,476</u>
Depreciation at 1 January 2021	(1,180)	(2,564)	(24,907)	(28,651)
Depreciation	(500)	(1,821)	(5,591)	(7,912)
Disposal	-	-	3,909	3,909
Reclassification	647	(2)	(645)	0
Depreciation at 31 December 2021	<u>(1,033)</u>	<u>(4,387)</u>	<u>(27,234)</u>	<u>(32,654)</u>
Carrying amount at 31 December 2021	<u>1,204</u>	<u>17,824</u>	<u>39,794</u>	<u>58,822</u>
Depreciated over	3-5 years	5-10 years	3-10 years	

6 Prepayments

Prepayments of DKK 737 thousand (2020: DKK 449 thousand) are mainly related to prepaid service contracts and prepaid salary.

Notes to the financial statements

7	Share capital comprises of:		TDKK
	Share capital of DKK 1.00		100,133
	Development in share capital		
	Share capital as per 31 December 2017		100,133
	Capital increase 2018		-
	Capital increase 2019		-
	Capital increase 2020		-
	Capital increase 2021		-
	Share capital as per 31 December 2021		<u>100,133</u>
	<i>All shares rank equally.</i>		
		2021	2020
		TDKK	TDKK
8	Other Payables		
	Employee related compensation and benefits	11,950	2,818
	Non-current liabilities other than provisions	-	4,979
	Other	3,603	14,201
	Total other payables	<u>15,553</u>	<u>21,998</u>
9	Deferred Tax Liability		
	Deferred tax at 1 January 2021	4,700	1,919
	Adjustment for the year in the income statement	466	2,781
	Adjustment from prior year	(222)	-
	Deferred tax liability total	<u>4,943</u>	<u>4,700</u>
	Deferred tax relates to		
	PP&E	4,781	5,997
	Deferred income	162	(99)
	Equity compensation plans	-	(845)
	Deferred Tax Asset - Restructuring Provision	-	(353)
	Deferred tax liability total	<u>4,943</u>	<u>4,700</u>

Notes to the financial statements

10 Contingencies, etc.

Lease obligations

The Company has entered into operating leases regarding car and other equipments. The remaining payments for lease obligations amount to DKK 1.056 thousand (2020: DKK 1.065 thousand) of which DKK 432 thousand is due within the next 12 months.

Rent obligations

The Company leases office and laboratory space under a cancellable operation lease agreement, subject to a 6 months notification period. Therefore, a lease term of six months is considered as the company's commitment which equals DKK 4,375 thousands as of December 31, 2021 for a yearly rent of DKK 8,750 thousands.

Contingent Assets

The Danish Tax Agency (Skattestyrelsen) has adjusted RICC A/S' taxable income for the year 2015. RICC A/S has appealed the decision from Skattestyrelsen to the Danish Tax Tribunal, as management believes the company's taxable income for 2015 is correct.

On November 18, 2020 the company paid an amount of DKK 288 million to Skattestyrelsen, to avoid interest and penalties, which will be paid back fully/partly if the appeal of RICC A/S is fully/partly heard. The amount cannot be determined at this stage.

Tax obligations

The company participates in a Danish joint taxation arrangement in which Roche A/S (CVR 25230515) serves as the administration company. According to the joint taxation provision rules in the Danish Corporation Tax Act, the company is therefore liable from 2 September 2014 for income taxes etc., obligations, if any, relating to the withholding of tax on interest, royalties and dividends for the jointly taxed companies.

11 Related party disclosures and transactions

The company is a 100% owned subsidiary. The company is part of the consolidated financial statements of Roche Holding AG, Grenzacherstrasse 124, 4002 Basel, Switzerland, in which the Company is included as a subsidiary.

The consolidated financial statements of Roche Holding AG can be obtained by contacting the Company or at the following website: <https://www.roche.com/investors/annualreport21.htm>.

Transactions with related parties consist exclusively of purchasing goods and services, selling goods and services as well as licensing and selling intellectual property to/from group companies.

Notes to the financial statements

	2021	2020
	TDKK	TDKK
Related party transactions		
Purchase of services/goods from group enterprises	(10,009)	(41,336)
Sale of services/goods sold to group enterprises	171,170	142,693
Income relating to intangible assets from group enterprises	-	156,879
Expenses relating to intangible assets	(23)	(25)
Total related party transactions	<u>161,138</u>	<u>258,211</u>

Purchase of products and services are bought from group enterprises on normal commercial terms and conditions.

The company's balances with group enterprises at December 31, 2021 are recognized in the balance sheet. Interest income and expenses with respect to group enterprises are disclosed in note 3. Further, balances with group enterprises comprise trade balances related to the purchase and sale of goods and services.

Purchases of services and goods from group enterprises consist of instruments, reagents and chemicals used in the laboratories as well as laboratory equipment services. Sale of services and goods to group enterprises consist of R&D services and LNA-Monomers used for R&D. Income relating to intangible assets consists of selling intellectual property rights to group enterprises. Expenses relating to intangible assets consists of licensing intellectual property rights from group enterprises.

No transactions have been carried out with the Board of Directors, the Executive Management, senior employees, major shareholders or other related parties, apart from ordinary remuneration.

Certificate Of Completion

Envelope Id: 08FE4CD3EC9B4F4AAC1E319AAC643C46	Status: Completed
Subject: Please DocuSign: URGENT - RICC Annual Report 2021 - 30.06.2022	
Source Envelope:	
Document Pages: 24	Signatures: 5
Certificate Pages: 4	Initials: 0
AutoNav: Enabled	Envelope Originator:
Envelopeld Stamping: Enabled	Sandra Schatz
Time Zone: (UTC+01:00) Amsterdam, Berlin, Bern, Rome, Stockholm, Vienna	Grenzacherstrasse 124
	Basel, Basel-Stadt 4070
	sandra.schatz@roche.com
	IP Address: 46.126.62.94


Record Tracking

Status: Original	Holder: Sandra Schatz	Location: DocuSign
6/30/2022 10:54:29 AM	sandra.schatz@roche.com	

Signer Events

Beat Krähenmann
beat.kraehenmann@roche.com
SES RE - Parent_408
Security Level: Email, Account Authentication (None)

Signature


DocuSigned by:

E9962517519B46F...
Signature Adoption: Pre-selected Style
Signed by link sent to
beat.kraehenmann@roche.com
Using IP Address: 62.202.183.35

Timestamp

Sent: 6/30/2022 11:00:00 AM
Viewed: 6/30/2022 11:01:35 AM
Signed: 6/30/2022 11:02:26 AM

Electronic Record and Signature Disclosure:
Not Offered via DocuSign


Darine Ghanem
darine.ghanem@roche.com
Roche Copenhagen
Security Level: Email, Account Authentication (None)

DocuSigned by:

5C7AF7211CE040B...
Signature Adoption: Pre-selected Style
Signed by link sent to darine.ghanem@roche.com
Using IP Address: 196.3.50.247

Sent: 6/30/2022 11:00:01 AM
Viewed: 6/30/2022 11:00:33 AM
Signed: 6/30/2022 11:03:12 AM


Electronic Record and Signature Disclosure:
Accepted: 6/29/2020 5:56:08 PM
ID: f7b35d3c-5582-4bbc-99d6-3080435b884a

Louise Homøe
louise.homoe@roche.com
Roche Diagnostics A/S
Security Level: Email, Account Authentication (None)

DocuSigned by:

7E0FFC98A5784BD...
Signature Adoption: Pre-selected Style
Signed by link sent to louise.homoe@roche.com
Using IP Address: 185.229.155.12

Sent: 6/30/2022 11:00:01 AM
Viewed: 6/30/2022 2:50:01 PM
Signed: 6/30/2022 2:50:18 PM

Electronic Record and Signature Disclosure:
Accepted: 6/30/2022 2:48:22 PM
ID: 47a7592f-6d2c-4341-9cb2-c30891d44183

Signer Events	Signature	Timestamp
<p>Sylke Poehling sylke.poehling@roche.com Security Level: Email, Account Authentication (None)</p>	<p>DocuSigned by:  519A27883F0459...</p> <p>Signature Adoption: Pre-selected Style Signed by link sent to sylke.poehling@roche.com Using IP Address: 178.197.226.25</p>	<p>Sent: 6/30/2022 11:00:01 AM Viewed: 6/30/2022 11:01:17 AM Signed: 6/30/2022 11:01:58 AM</p>

Electronic Record and Signature Disclosure:
Accepted: 6/30/2022 11:18:08 AM
ID: 5528c4bf-ccb8-412d-8ad5-3edc934fbf1a

In Person Signer Events	Signature	Timestamp
-------------------------	-----------	-----------

Editor Delivery Events	Status	Timestamp
------------------------	--------	-----------

Agent Delivery Events	Status	Timestamp
-----------------------	--------	-----------

Intermediary Delivery Events	Status	Timestamp
------------------------------	--------	-----------

Certified Delivery Events	Status	Timestamp
---------------------------	--------	-----------

Carbon Copy Events	Status	Timestamp
--------------------	--------	-----------

<p>Sandra Schatz@roche.com sandra.schatz@roche.com SES RE - Parent_408 Security Level: Email, Account Authentication (None)</p> <p>Electronic Record and Signature Disclosure: Not Offered via DocuSign</p>	<div style="border: 2px solid blue; padding: 5px; text-align: center; font-weight: bold; color: blue;">COPIED</div>	<p>Sent: 6/30/2022 11:00:01 AM Resent: 6/30/2022 2:50:22 PM Viewed: 6/30/2022 3:07:58 PM</p>
--	---	--

<p>veronika fuggler veronika.fuggler@roche.com SES RE - Parent_408 Security Level: Email, Account Authentication (None)</p> <p>Electronic Record and Signature Disclosure: Not Offered via DocuSign</p>	<div style="border: 2px solid blue; padding: 5px; text-align: center; font-weight: bold; color: blue;">COPIED</div>	<p>Sent: 6/30/2022 11:00:02 AM</p>
--	---	------------------------------------

Witness Events	Signature	Timestamp
----------------	-----------	-----------

Notary Events	Signature	Timestamp
---------------	-----------	-----------

Envelope Summary Events	Status	Timestamps
-------------------------	--------	------------

Envelope Sent	Hashed/Encrypted	6/30/2022 11:00:02 AM
Certified Delivered	Security Checked	6/30/2022 11:01:17 AM
Signing Complete	Security Checked	6/30/2022 11:01:58 AM
Completed	Security Checked	6/30/2022 2:50:18 PM

Payment Events	Status	Timestamps
----------------	--------	------------

Electronic Record and Signature Disclosure
--

Guidelines for the use of the DocuSign electronic signing system within F. Hoffmann-La Roche and companies of the Roche Group

LEGAL DISCLOSURE

By placing my electronic signature on this document, I expressly consent to use and rely on Electronic and Digital Signatures and I understand my signature will have the same binding effect as if I was providing a handwritten signature.

I also confirm the email address that I am using as a valid one to be notified and identified electronically, for example through the DocuSign System, and/or to identify me as the signer of the document. I should inform Roche in the case that the email address changes.

CONSUMER DISCLOSURE

From time to time, F. Hoffmann-La Roche and companies of the Roche Group (hereinafter referred to as we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your consent by clicking the 'I agree' button at the bottom of this document.

Consequences of changing your mind

To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign 'Withdraw Consent' form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact us

You may contact us to let us know of your changes as to how we may contact you electronically, to request certain information from us and to withdraw your prior consent to receive notices and disclosures electronically. To do so contact the sender of the envelope.

To advise us of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to the sender of the envelope and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address. In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing email in the DocuSign system.

To withdraw your consent

To inform us that you no longer want to receive future notices and disclosures in electronic format you may decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent.

Acknowledging your access and consent to receive materials electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to email this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the 'I agree' button below.

By checking the 'I agree' box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify the account owner as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by the account owner during the course of my relationship with you.
- I acknowledge the information included in the [DocuSign Privacy Policy](#)